- Home
- RRR vs SWTX Comparison
RRR vs SWTX Comparison
Compare RRR & SWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RRR
- SWTX
- Stock Information
- Founded
- RRR 1976
- SWTX 2017
- Country
- RRR United States
- SWTX United States
- Employees
- RRR N/A
- SWTX N/A
- Industry
- RRR Hotels/Resorts
- SWTX Biotechnology: Pharmaceutical Preparations
- Sector
- RRR Consumer Discretionary
- SWTX Health Care
- Exchange
- RRR Nasdaq
- SWTX Nasdaq
- Market Cap
- RRR 3.0B
- SWTX 3.0B
- IPO Year
- RRR 2016
- SWTX 2019
- Fundamental
- Price
- RRR $44.86
- SWTX $47.21
- Analyst Decision
- RRR Buy
- SWTX Strong Buy
- Analyst Count
- RRR 13
- SWTX 5
- Target Price
- RRR $57.92
- SWTX $72.40
- AVG Volume (30 Days)
- RRR 571.4K
- SWTX 2.1M
- Earning Date
- RRR 05-06-2025
- SWTX 05-01-2025
- Dividend Yield
- RRR 2.24%
- SWTX N/A
- EPS Growth
- RRR N/A
- SWTX N/A
- EPS
- RRR 2.53
- SWTX N/A
- Revenue
- RRR $1,939,011,000.00
- SWTX $191,589,000.00
- Revenue This Year
- RRR $2.22
- SWTX $85.98
- Revenue Next Year
- RRR $2.98
- SWTX $69.16
- P/E Ratio
- RRR $17.65
- SWTX N/A
- Revenue Growth
- RRR 12.47
- SWTX 3417.33
- 52 Week Low
- RRR $42.33
- SWTX $28.21
- 52 Week High
- RRR $63.29
- SWTX $62.00
- Technical
- Relative Strength Index (RSI)
- RRR 43.07
- SWTX 43.26
- Support Level
- RRR $42.92
- SWTX $47.70
- Resistance Level
- RRR $45.89
- SWTX $51.43
- Average True Range (ATR)
- RRR 1.43
- SWTX 2.42
- MACD
- RRR 0.00
- SWTX -0.72
- Stochastic Oscillator
- RRR 51.12
- SWTX 8.43
About RRR Red Rock Resorts Inc.
Red Rock Resorts Inc along with its subsidiary is a gaming, development, and management company. The company mainly develops strategically located casino and entertainment properties. It generates a majority of its revenue from Casino.
About SWTX SpringWorks Therapeutics Inc.
SpringWorks Therapeutics Inc is a clinical stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing highly prevalent, genetically defined cancers.